α5β1-integrin expression is essential for tumor progression in experimental lung cancer

American Journal of Respiratory Cell and Molecular Biology

Volumn 43, Issue 6, 2010, Pages 684-691

  Roman, Jesse ^a,b   Ritzenthaler, Jeffrey D ^a   Roser Page, Sussane ^a,c   Sun, XiaoJuan ^a   Han, ShouWei ^a  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 1 integrin; Fibronectin; Lewis lung carcinoma; Lung cancer; Short hairpin RNA shRNA

Indexed keywords

AGAR; ALPHA2 INTEGRIN; ALPHA5 INTEGRIN; FIBRONECTIN; SHORT HAIRPIN RNA; VERY LATE ACTIVATION ANTIGEN 5; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SIZE; CARCINOMA CELL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; LUNG CARCINOGENESIS; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL MOTION; DISEASE COURSE; DRUG SCREENING; GENE SILENCING; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; METABOLISM; METASTASIS; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL;

MURINAE; MUS;

AGAR; ANIMALS; CARCINOMA, LEWIS LUNG; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FIBRONECTINS; GENE SILENCING; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTEGRIN ALPHA5BETA1; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TUMOR STEM CELL ASSAY;

EID: 78649720692     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0375OC     Document Type: Article

References (47)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, Dasgupta A, Mann FE, Fukuoka J, Hames M, Bergen AW, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS ONE 2008;3:e1651. (Pubitemid 351865456)
3. Bryant A, Cerfolio RJ. Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 2007;132:185-192. (Pubitemid 47068220)
4. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, Hatton M, Hopwood P, Manegold C, Schramel F, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-1937.
5. Hirtenlehne K, Pec M, Kubista E, Singer CF. Extracellular matrix proteins influence phenotype and cytokine expression in human breast cancer cell lines. Eur Cytokine Netw 2002;13:234-240. (Pubitemid 34747925)
6. Gutierrez-Fernandez A, Fueyo A, Folgueras AR, Garabaya C, Pennington CJ, Pilgrim S, Edwards DR, Holliday DL, Jones JL, Span PN, et al. Matrix metalloproteinase-8 functions as a metastasis suppressor through modulation of tumor cell adhesion and invasion. Cancer Res 2008;68:2755-2763.
7. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP. The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin cd151. Cancer Cell 2008;13:221-234. (Pubitemid 351318371)
8. Hynes RO, Yamada KM. Fibronectins: multifunctional modular glycoproteins. J Cell Biol 1982;95:369-377.
9. Ritzenthaler JD, Han S, Roman J. Stimulation of lung carcinoma cell growth by fibronectin-integrin signalling. Mol Biosyst 2008;4:1160-1169.
10. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002;12:187-195.
11. Williams CM, Engler AJ, Slone RD, Galante LL, Schwarzbauer JE. Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res 2008;68:3185-3192.
12. Oyama F, Hirohashi S, Shimosato Y, Titani K, Sekiguchi K. Oncodevelopmental regulation of the alternative splicing of fibronectin premessenger RNA in human lung tissues. Cancer Res 1990;50:1075-1078. (Pubitemid 20083989)
13. Rintoul RC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci 2002;102:417-424.
14. Han S, Ritzenthaler JD, Wingerd B, Rivera HN, Roman J. Extracellular matrix fibronectin increases prostaglandin E2 receptor subtype EP4 in lung carcinoma cells through multiple signaling pathways: the role of AP-2. J Biol Chem 2007;282:7961-7972.
15. Han S, Sidell N, Roser-Page S, Roman J. Fibronectin stimulates human lung carcinoma cell growth by inducing cyclooxygenase-2 (COX-2) expression. Int J Cancer 2004;111:322-331.
16. Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006;66:315-323.
17. Han S, Ritzenthaler JD, Sitaraman SV, Roman J. Fibronectin increases matrix metalloproteinase 9 expression through activation of c-FOS via extracellular-regulated kinase and phosphatidylinositol 3-kinase pathways in human lung carcinoma cells. J Biol Chem 2006;281:29614-29624.
18. Gaggioli C, Robert G, Bertolotto C, Bailet O, Abbe P, Spadafora A, Bahadoran P, Ortonne JP, Baron V, Ballotti R, et al. Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway. J Invest Dermatol 2007;127:400-410.
19. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H, Hynes RO. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 1993;119:1079-1091.
20. Akiyama SK. Integrins in cell adhesion and signaling. Hum Cell 1996;9:181-186.
21. Kuwada SK, Kuang J, Li X. Integrin alpha5/beta1 expression mediates HER-2 down-regulation in colon cancer cells. J Biol Chem 2005;280:19027-19035.
22. Murillo CA, Rychahou PG, Evers BM. Inhibition of alpha5 integrin decreases PI3K activation and cell adhesion of human colon cancers. Surgery 2004;136:143-149.
23. Adachi M, Taki T, Higashiyama M, Kohno N, Inufusa H, Miyake M. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer. Clin Cancer Res 2000;6:96-101.
24. Saito T, Kimura M, Kawasaki T, Sato S, Tomita Y. Correlation between integrin alpha 5 expression and the malignant phenotype of transitional cell carcinoma. Br J Cancer 1996;73:327-331.
25. Han S, Ritzenthaler JD, Wingerd B, Roman J. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) increases the expression of prostaglandin E2 receptor subtype EP4: the roles of phosphatidylinositol 3-kinase and CCAAT/enhancer-binding protein beta. J Biol Chem 2005;280:33240-33249.
26. Kuwada SK. Drug evaluation: volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody. Curr Opin Mol Ther 2007;9:92-98.
27. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 2008;68:2329-2339.
28. Bhaskar V, Zhang D, Fox M, Seto P, Wong MH, Wales PE, Powers D, Chao DT, Dubridge RB, Ramakrishnan V. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo. J Transl Med 2007;5:61.
29. Ramakrishnan V, Bhaskar V, Law DA, Wong MH, DuBridge RB, Breinberg D, O'Hara C, Powers DB, Liu G, Grove J, et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel antiangiogenic agent. J Exp Ther Oncol 2006;5:273-286.
30. Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM, Stanners CP. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol 2007;210:757-765.
31. Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 2008;68:7237-7245.
32. Cui R, Ohashi R, Takahashi F, Yoshioka M, Tominaga S, Sasaki S, Gu T, Takagi Y, Takahashi K. Signal transduction mediated by endostatin directly modulates cellular function of lung cancer cells in vitro. Cancer Sci 2007;98:830-837.
33. Urtreger AJ, Werbajh SE, Verrecchia F, Mauviel A, Puricelli LI, Kornblihtt AR, Bal de Kier Joffe ED. Fibronectin is distinctly downregulated in murine mammary adenocarcinoma cells with high metastatic potential. Oncol Rep 2006;16:1403-1410.
34. Zhou GF, Ye F, Cao LH, Zha XL. Over expression of integrin alpha 5 beta 1 in human hepatocellular carcinoma cell line suppresses cell proliferation in vitro and tumorigenicity in nude mice. Mol Cell Biochem 2000;207:49-55.
35. Taverna D, Ullman-Cullere M, Rayburn H, Bronson RT, Hynes RO. A test of the role of alpha5 integrin/fibronectin interactions in tumorigenesis. Cancer Res 1998;58:848-853.
36. Yi M, Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc Natl Acad Sci USA 2001;98:620-624.
37. Hsu SL, Cheng CC, Shi YR, Chiang CW. Proteolysis of integrin alpha5 and beta1 subunits involved in retinoic acid-induced apoptosis in human hepatoma HEP3B cells. Cancer Lett 2001;167:193-204.
38. Morozevich GE, Kozlova NI, Cheglakov IB, Ushakova NA, Preobrazhenskaya ME, Berman AE. Implication of alpha5beta1 integrin in invasion of drug-resistant MCF-7/ADR breast carcinoma cells: a role for MMP-2 collagenase. Biochemistry 2008;73:791-796.
39. Sethi T, Rintoul RC, Moore SM, MacKinnon AC, Salter D, Choo C, Chilvers ER, Dransfield I, Donnelly SC, Strieter R, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-668.
40. Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, Hynes RO. Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol 2004;24:8662-8670.
41. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002;3:409-421.
42. Nakstad B, Boye NP, Lyberg T. Distribution of bronchoalveolar cells and fibronectin levels in bronchoalveolar lavage fluids from patients with lung disorders. Scand J Clin Lab Invest 1990;50:587-593.
43. Roman J, Ritzenthaler JD, Gil-Acosta A, Rivera HN, Roser-Page S. Nicotine and fibronectin expression in lung fibroblasts: implications for tobacco-related lung tissue remodeling. FASEB J 2004;18:1436-1438.
44. Zheng Y, Ritzenthaler JD, Roman J, Han S. Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. Am J Respir Cell Mol Biol 2007;37:681-690.
45. Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands - design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 2007;7:552-558.
46. Ruoslahti E. Integrins as signaling molecules and targets for tumor therapy. Kidney Int 1997;51:1413-1417. (Pubitemid 27239891)
47. Kunath K, Merdan T, Hegener O, Haberlein H, Kissel T. Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J Gene Med 2003;5:588-599.